Ra Capital Management, L.p. bought $1.5M of JBIO
director, owner at Aerovate Therapeutics, Inc.. 928,110 shares at an average of $1.67, traded Jun 17, 2024, filed Jun 20, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.5M at market
- +3Relative to holdingsHoldings up 13%
- +18Price context0% above the 52-week low; 95% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -15% over 22 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.9%, 3m +35.6%, 6m +73.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-017703, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 17, 2024 | POpen-market purchase Common Stockindirect: See footnotes | +928,110 | $1.67 | $1.5M | 7,893,678 | Jun 20, 2024 |
Related signals
Other insiders at Aerovate Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | JBIObuy Aerovate Therapeutics, Inc. | Tom Frohlich Chief Executive Officer | $44k 6,000 shares | - | |
| 26Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $147k 6,000 shares | -52% | |
| 28Weak | Aerovate Therapeutics, Inc. | Marinus Verwijs CHIEF TECHNICAL OFFICER | $265k 10,600 shares | -100% | |
| 31Weak | Aerovate Therapeutics, Inc. | George A Eldridge SEE REMARKS | $375k 15,000 shares | -75% | |
| 37Weak | Aerovate Therapeutics, Inc. | Timothy P Noyes CHIEF EXECUTIVE OFFICER | $216k 10,000 shares | -100% | |
| 7Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $84k 4,000 shares | -42% | |
| 38Weak | Aerovate Therapeutics, Inc. | Timothy P Noyes CHIEF EXECUTIVE OFFICER | $231k 11,357 shares | -114% | |
| 49Moderate | Aerovate Therapeutics, Inc. | Marinus Verwijs CHIEF TECHNICAL OFFICER | $42k 1,981 shares | -100% | |
| 24Weak | Aerovate Therapeutics, Inc. | Hunter Gillies CHIEF MEDICAL OFFICER | $90k 4,000 shares | -55% | |
| 26Weak | Aerovate Therapeutics, Inc. | Benjamin T Dake SEE REMARKS | $153k 6,853 shares | -84% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.